Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BOSTON SCIENTIFIC CORPBSX · Entity 1897 | EVP, GC and Corp. Secretary | February 13, 2026 | February 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BOSTON SCIENTIFIC CORP
Report date February 13, 2026 · Filed February 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 54,244 |
Ending reported balance
After 2026-02-16 transaction · row 8
8 source rows · reconciled sequenceRow 1 · 2026-02-13 · Grant · Acquired 14,804 · Balance 49,209 F1: On February 14, 2023, the reporting person was awarded a target number of performance share units under the Company's 2023 Total Shareholder Return Performance Share Program, with the actual number to be earned by the reporting person to be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Health Care Index over the three-year performance cycle comprising the three-year period ended December 31, 2025 and subject to the completion of the concurrent three-year individual service period. On February 13, 2026, the number of performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied. Row 2 · 2026-02-13 · Grant · Acquired 14,804 · Balance 64,013 F2: On February 14, 2023, the reporting person was awarded a target number of performance share units under the Company's 2023 Organic Net Sales Performance Share Program, with the actual number to be earned by the reporting person to be based on the Company's organic net sales performance measured against its financial plan over the three-year performance cycle comprising the three-year period ended December 31, 2025 and subject to the completion of the concurrent three-year individual service period. On February 13, 2026, the number of performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied. Row 3 · 2026-02-13 · Exercise / conversion · Acquired 1,118 · Balance 65,131 F3: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Row 4 · 2026-02-13 · Tax withholding · Disposed 12,792 · Balance 52,339 Row 5 · 2026-02-14 · Exercise / conversion · Acquired 1,851 · Balance 54,190 F3: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Row 6 · 2026-02-14 · Tax withholding · Disposed 895 · Balance 53,295 Row 7 · 2026-02-16 · Exercise / conversion · Acquired 1,839 · Balance 55,134 F3: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Row 8 · 2026-02-16 · Tax withholding · Disposed 890 · Balance 54,244 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2029-02-13 | Direct | 3,357 |
Reported balance
After 2026-02-13 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-02-13 · Exercise / conversion · Disposed 1,118 · Balance 3,357 F3: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2027-02-14 | Direct | 1,851 |
Reported balance
After 2026-02-14 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-02-14 · Exercise / conversion · Disposed 1,851 · Balance 1,851 F3: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F5: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2026-02-16 | Direct | 0 |
Reported balance
After 2026-02-16 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-02-16 · Exercise / conversion · Disposed 1,839 · Balance 0 F3: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F6: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: On February 14, 2023, the reporting person was awarded a target number of performance share units under the Company's 2023 Total Shareholder Return Performance Share Program, with the actual number to be earned by the reporting person to be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Health Care Index over the three-year performance cycle comprising the three-year period ended December 31, 2025 and subject to the completion of the concurrent three-year individual service period. On February 13, 2026, the number of performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied.
F2: On February 14, 2023, the reporting person was awarded a target number of performance share units under the Company's 2023 Organic Net Sales Performance Share Program, with the actual number to be earned by the reporting person to be based on the Company's organic net sales performance measured against its financial plan over the three-year performance cycle comprising the three-year period ended December 31, 2025 and subject to the completion of the concurrent three-year individual service period. On February 13, 2026, the number of performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied.
F3: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
F4: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant.
F5: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant.
F6: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 21, 2024 Filed May 23, 2024 20:11 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 18,037 | $24.55 | $442,808.35 |
DisclosureSEC source: 0001225208-24-006324 · doc4.xml · nonDerivative · entry 1 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,363 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 20, 2024. Read SEC document |
| February 18, 2024 Filed Feb 21, 2024 02:03 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 741 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-002572 · doc4.xml · derivative · entry 9 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 741 shares Expires 2024-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue on share of Boston Scientific common stock. F5 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. F5 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. Read SEC document |
| February 18, 2024 Filed Feb 21, 2024 02:03 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 218 | $65.82 | $14,348.76 |
DisclosureSEC source: 0001225208-24-002572 · doc4.xml · nonDerivative · entry 6 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,326 Read SEC document |
| February 18, 2024 Filed Feb 21, 2024 02:03 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 741 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-002572 · doc4.xml · nonDerivative · entry 5 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,544 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each deferred stock unit represents the Company's commitment to issue on share of Boston Scientific common stock. Read SEC document |
| February 17, 2024 Filed Feb 21, 2024 02:03 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionRestricted Stock Units · Derivative | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-002572 · doc4.xml · derivative · entry 8 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000 Underlying: Common Stock · 1,000 shares Expires 2025-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. Read SEC document |
| February 17, 2024 Filed Feb 21, 2024 02:03 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 294 | $65.82 | $19,351.08 |
DisclosureSEC source: 0001225208-24-002572 · doc4.xml · nonDerivative · entry 4 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,803 Read SEC document |
| February 17, 2024 Filed Feb 21, 2024 02:03 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-002572 · doc4.xml · nonDerivative · entry 3 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,097 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 02:03 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionRestricted Stock Units · Derivative | 1,838 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-002572 · doc4.xml · derivative · entry 7 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,678 Underlying: Common Stock · 1,838 shares Expires 2026-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 02:03 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 540 | $65.82 | $35,542.80 |
DisclosureSEC source: 0001225208-24-002572 · doc4.xml · nonDerivative · entry 2 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,097 Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 02:03 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 1,838 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-002572 · doc4.xml · nonDerivative · entry 1 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,637 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 21:21 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionRestricted Stock Units · Derivative | 1,850 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-002301 · doc4.xml · derivative · entry 3 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,552 Underlying: Common Stock · 1,850 shares Expires 2027-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 21:21 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 629 | $65.95 | $41,482.55 |
DisclosureSEC source: 0001225208-24-002301 · doc4.xml · nonDerivative · entry 2 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,799 Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 21:21 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 1,850 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-002301 · doc4.xml · nonDerivative · entry 1 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,428 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:19 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantStock Option (Right to Buy) · Derivative | 15,212 | $0.00 Strike: $64.99 | $0.00 |
DisclosureSEC source: 0001225208-24-002037 · doc4.xml · derivative · entry 2 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,212 Underlying: Common Stock · 15,212 shares Expires 2034-02-12 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:19 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantRestricted Stock Units · Derivative | 5,770 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-002037 · doc4.xml · derivative · entry 1 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,770 Underlying: Common Stock · 5,770 shares Expires 2028-02-12 F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. Read SEC document |
| August 25, 2023 Filed Aug 28, 2023 20:18 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 15,750 | $50.52 | $795,756.15 |
DisclosureSEC source: 0001225208-23-008498 · doc4.xml · nonDerivative · entry 1 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,578 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on May 26, 2023. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $50.45 to $50.61, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 01, 2023 Filed Jul 3, 2023 20:14 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionRestricted Stock Units · Derivative | 4,036 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-007117 · doc4.xml · derivative · entry 3 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,072 Underlying: Common Stock · 4,036 shares Expires 2025-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on July 1, 2022, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on July 1, 2022, the first anniversary of the date of grant. Read SEC document |
| July 01, 2023 Filed Jul 3, 2023 20:14 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 1,359 | $54.09 | $73,508.31 |
DisclosureSEC source: 0001225208-23-007117 · doc4.xml · nonDerivative · entry 2 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,328 Read SEC document |
| July 01, 2023 Filed Jul 3, 2023 20:14 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 4,036 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-007117 · doc4.xml · nonDerivative · entry 1 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,687 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 21, 2023 Filed Feb 22, 2023 21:54 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 779 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002526 · doc4.xml · derivative · entry 3 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 779 shares Expires 2023-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. Read SEC document |
| February 21, 2023 Filed Feb 22, 2023 21:54 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 229 | $46.23 | $10,586.67 |
DisclosureSEC source: 0001225208-23-002526 · doc4.xml · nonDerivative · entry 2 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,651 Read SEC document |
| February 21, 2023 Filed Feb 22, 2023 21:54 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 779 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002526 · doc4.xml · nonDerivative · entry 1 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,880 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 18, 2023 Filed Feb 21, 2023 21:16 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 741 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002370 · doc4.xml · derivative · entry 9 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 741 Underlying: Common Stock · 741 shares Expires 2024-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue on share of Boston Scientific common stock. F5 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. F5 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. Read SEC document |
| February 18, 2023 Filed Feb 21, 2023 21:16 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 218 | $46.54 | $10,145.72 |
DisclosureSEC source: 0001225208-23-002370 · doc4.xml · nonDerivative · entry 6 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,101 Read SEC document |
| February 18, 2023 Filed Feb 21, 2023 21:16 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 741 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002370 · doc4.xml · nonDerivative · entry 5 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,319 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each deferred stock unit represents the Company's commitment to issue on share of Boston Scientific common stock. Read SEC document |
| February 17, 2023 Filed Feb 21, 2023 21:16 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionRestricted Stock Units · Derivative | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002370 · doc4.xml · derivative · entry 8 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 1,000 shares Expires 2025-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. Read SEC document |
| February 17, 2023 Filed Feb 21, 2023 21:16 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 294 | $46.54 | $13,682.76 |
DisclosureSEC source: 0001225208-23-002370 · doc4.xml · nonDerivative · entry 4 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,578 Read SEC document |
| February 17, 2023 Filed Feb 21, 2023 21:16 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002370 · doc4.xml · nonDerivative · entry 3 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,872 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 21:16 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionRestricted Stock Units · Derivative | 1,838 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002370 · doc4.xml · derivative · entry 7 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,516 Underlying: Common Stock · 1,838 shares Expires 2026-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 21:16 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 568 | $46.48 | $26,400.64 |
DisclosureSEC source: 0001225208-23-002370 · doc4.xml · nonDerivative · entry 2 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,872 Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 21:16 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 1,838 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002370 · doc4.xml · nonDerivative · entry 1 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,440 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 00:15 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 923 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002149 · doc4.xml · derivative · entry 3 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 923 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 00:15 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 323 | $47.29 | $15,274.67 |
DisclosureSEC source: 0001225208-23-002149 · doc4.xml · nonDerivative · entry 2 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,602 Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 00:15 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 923 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002149 · doc4.xml · nonDerivative · entry 1 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,925 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 14, 2023 Filed Feb 15, 2023 22:42 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantStock Option (Right to Buy) · Derivative | 19,262 | $0.00 Strike: $47.28 | $0.00 |
DisclosureSEC source: 0001225208-23-002033 · doc4.xml · derivative · entry 3 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,262 Underlying: Common Stock · 19,262 shares Expires 2033-02-14 F5 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. Read SEC document |
| February 14, 2023 Filed Feb 15, 2023 22:42 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantRestricted Stock Units · Derivative | 7,402 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002033 · doc4.xml · derivative · entry 2 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,402 Underlying: Common Stock · 7,402 shares Expires 2027-02-14 F3 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. Read SEC document |
| February 14, 2023 Filed Feb 15, 2023 22:42 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantPerformance Share Units · Derivative | 6,456 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002033 · doc4.xml · derivative · entry 1 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,456 Underlying: Common Stock · 6,456 shares Expires 2024-12-31 F1 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · shares: On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2024. F2 · derivative.exercise_date: On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2024. F2 · derivative.expiration_date: On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2024. F2 · balance_after: On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2024. Read SEC document |
| October 02, 2022 Filed Oct 4, 2022 20:36 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 3,394 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-010698 · doc4.xml · derivative · entry 3 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,394 shares Expires 2022-10-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on October 2, 2018, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on October 2, 2018, the first anniversary of the date of grant. Read SEC document |
| October 02, 2022 Filed Oct 4, 2022 20:36 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 997 | $38.73 | $38,613.81 |
DisclosureSEC source: 0001225208-22-010698 · doc4.xml · nonDerivative · entry 2 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,002 Read SEC document |
| October 02, 2022 Filed Oct 4, 2022 20:36 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 3,394 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-010698 · doc4.xml · nonDerivative · entry 1 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,999 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| July 01, 2022 Filed Jul 6, 2022 20:55 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionRestricted Stock Units · Derivative | 4,035 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-008661 · doc4.xml · derivative · entry 3 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,108 Underlying: Common Stock · 4,035 shares Expires 2025-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on July 1, 2022, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on July 1, 2022, the first anniversary of the date of grant. Read SEC document |
| July 01, 2022 Filed Jul 6, 2022 20:55 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 1,185 | $38.01 | $45,041.85 |
DisclosureSEC source: 0001225208-22-008661 · doc4.xml · nonDerivative · entry 2 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,605 Read SEC document |
| July 01, 2022 Filed Jul 6, 2022 20:55 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 4,035 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-008661 · doc4.xml · nonDerivative · entry 1 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,790 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 21:26 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 1,019 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-003856 · doc4.xml · derivative · entry 3 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,019 shares Expires 2022-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 21:26 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 300 | $44.17 | $13,251.00 |
DisclosureSEC source: 0001225208-22-003856 · doc4.xml · nonDerivative · entry 2 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,755 Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 21:26 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 1,019 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-003856 · doc4.xml · nonDerivative · entry 1 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,055 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 21, 2022 Filed Feb 23, 2022 21:14 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 779 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-003073 · doc4.xml · derivative · entry 3 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 779 Underlying: Common Stock · 779 shares Expires 2023-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. Read SEC document |
| February 21, 2022 Filed Feb 23, 2022 21:14 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 230 | $42.55 | $9,786.50 |
DisclosureSEC source: 0001225208-22-003073 · doc4.xml · nonDerivative · entry 2 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,036 Read SEC document |
| February 21, 2022 Filed Feb 23, 2022 21:14 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 779 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-003073 · doc4.xml · nonDerivative · entry 1 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,266 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 18, 2022 Filed Feb 22, 2022 21:43 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 741 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002914 · doc4.xml · derivative · entry 6 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,482 Underlying: Common Stock · 741 shares Expires 2024-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.